What is CRISPR Therapeutics's D&A?

CRISPR Therapeutics (CRSP) reported D&A of $4.32M in Q1 2026.

How has CRISPR Therapeutics's D&A changed year-over-year?

CRISPR Therapeutics's D&A decreased by 8.8% year-over-year, from $4.74M to $4.32M.

What is the long-term trend for CRISPR Therapeutics's D&A?

Over 4 years (2021 to 2025), CRISPR Therapeutics's D&A has grown at a 2.1% compound annual growth rate (CAGR), from $17.95M to $19.48M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

CRISPR Therapeutics CRSP D&A

D&A at other companies

PTC TherapeuticsPTCT

$11.58M+205%

Arrowhead ResearchARWR

——

RevvityRVTY

——

BiogenBIIB

——

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's D&A?: CRISPR Therapeutics (CRSP) reported D&A of $4.32M in Q1 2026.
How has CRISPR Therapeutics's D&A changed year-over-year?: CRISPR Therapeutics's D&A decreased by 8.8% year-over-year, from $4.74M to $4.32M.
What is the long-term trend for CRISPR Therapeutics's D&A?: Over 4 years (2021 to 2025), CRISPR Therapeutics's D&A has grown at a 2.1% compound annual growth rate (CAGR), from $17.95M to $19.48M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.